The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.